{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:30:42Z","timestamp":1793021442415,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570298"],"award-info":[{"award-number":["81570298"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970270"],"award-info":[{"award-number":["81970270"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["16JCZDJC34900"],"award-info":[{"award-number":["16JCZDJC34900"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetes mellitus is an important risk factor for atrial fibrillation (AF) development. Sodium\u2013glucose co-transporter-2 (SGLT-2) inhibitors are used for the treatment of type 2 diabetes mellitus (T2DM). Their cardioprotective effects have been reported but whether they prevent AF in T2DM patients are less well-explored. We tested the hypothesis that the SGLT-2 inhibitor, empagliflozin, can prevent atrial remodeling in a diabetic rat model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>High-fat diet and low-dose streptozotocin (STZ) treatment were used to induce T2DM. A total of 96 rats were randomized into the following four groups: (i) control (ii) T2DM, (iii) low-dose empagliflozin (10\u00a0mg\/kg\/day)\/T2DM; and (iv) high-dose empagliflozin (30\u00a0mg\/kg\/day)\/T2DM by the intragastric route for 8\u00a0weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with the control group, left atrial diameter, interstitial fibrosis and the incidence of AF inducibility were significantly increased in the DM group. Moreover, atrial mitochondrial respiratory function, mitochondrial membrane potential, and mitochondrial biogenesis were impaired. Empagliflozin treatment significantly prevented the development of these abnormalities in DM rats, likely via the peroxisome proliferator-activated receptor-c coactivator 1\u03b1 (PGC-1\u03b1)\/nuclear respiratory factor-1 (NRF-1)\/mitochondrial transcription factor A (Tfam) signaling pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Empagliflozin can ameliorate atrial structural and electrical remodeling as well as improve mitochondrial function and mitochondrial biogenesis in T2DM, hence may be potentially used in the prevention of T2DM-related atrial fibrillation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-019-0964-4","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T06:03:02Z","timestamp":1574920982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":278,"title":["Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats"],"prefix":"10.1186","volume":"18","author":[{"given":"Qingmiao","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0482-0738","authenticated-orcid":false,"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"issue":"8","key":"964_CR1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","volume":"27","author":"J Heeringa","year":"2006","unstructured":"Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949\u201353.","journal-title":"Eur Heart J"},{"issue":"9","key":"964_CR2","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/eurheartj\/ehp055","volume":"30","author":"X Du","year":"2009","unstructured":"Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J. 2009;30(9):1128\u201335.","journal-title":"Eur Heart J"},{"issue":"5","key":"964_CR3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.amjcard.2007.10.025","volume":"101","author":"TA Aksnes","year":"2008","unstructured":"Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol. 2008;101(5):634\u20138.","journal-title":"Am J Cardiol"},{"issue":"22","key":"964_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"964_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"7","key":"964_CR6","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/dom.12924","volume":"19","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, Fulcher G, Erondu N, Desai M, et al. Optimizing the analysis strategy for the CANVAS program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab. 2017;19(7):926\u201335.","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"964_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.jacc.2014.02.555","volume":"63","author":"S Nattel","year":"2014","unstructured":"Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22):2335\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"964_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/jdi.12235","volume":"5","author":"S Skovs\u00f8","year":"2014","unstructured":"Skovs\u00f8 S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Invest. 2014;5(4):349\u201358.","journal-title":"J Diabetes Invest"},{"issue":"3","key":"964_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.nlm.2010.06.008","volume":"94","author":"P Bhutada","year":"2010","unstructured":"Bhutada P, Mundhada Y, Bansod K, Bhutada C, Tawari S, Dixit P, et al. Ameliorative effect of quercetin on memory dysfunction in streptozotocin-induced diabetic rats. Neurobiol Learn Mem. 2010;94(3):293\u2013302.","journal-title":"Neurobiol Learn Mem"},{"key":"964_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/DMSO.S58786","volume":"7","author":"SP Vickers","year":"2014","unstructured":"Vickers SP, Cheetham SC, Headland KR, Dickinson K, Grempler R, Mayoux E, et al. Combination of the sodium\u2013glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes. 2014;7:265\u201375.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"6","key":"964_CR11","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1159\/000475942","volume":"41","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Wu W. The sodium\u2013glucose co-transporter 2 inhibitor, empagliflozin, protects against diabetic cardiomyopathy by inhibition of the endoplasmic reticulum stress pathway. Cell Physiol Biochem. 2017;41(6):2503\u201312.","journal-title":"Cell Physiol Biochem"},{"key":"964_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/0076-6879(95)60154-6","volume":"260","author":"M Reers","year":"1995","unstructured":"Reers M, Smiley ST, Mottola-Hartshorn C, Chen A, Lin M, Chen LB. Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol. 1995;260:406\u201317.","journal-title":"Methods Enzymol"},{"issue":"1","key":"964_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12933-017-0604-9","volume":"16","author":"BS Karam","year":"2017","unstructured":"Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017;16(1):120.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"964_CR14","first-page":"364","volume":"5","author":"F De Sensi","year":"2015","unstructured":"De Sensi F, De Potter T, Cresti A, Severi S, Breithardt G. Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives. Cardiovasc Diagn Ther. 2015;5(5):364\u201373.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"2","key":"964_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/jce.12540","volume":"26","author":"H Fu","year":"2015","unstructured":"Fu H, Li G, Liu C, Li J, Wang X, Cheng L, et al. Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-alpha\/NF-kappaB\/TGF-beta signal transduction pathway in alloxan-induced diabetic rabbits. J Cardiovasc Electrophysiol. 2015;26(2):211\u201322.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"964_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ijcard.2016.07.132","volume":"221","author":"J Qiu","year":"2016","unstructured":"Qiu J, Zhao J, Li J, Liang X, Yang Y, Zhang Z, et al. NADPH oxidase inhibitor apocynin prevents atrial remodeling in alloxan-induced diabetic rabbits. Int J Cardiol. 2016;221:812\u20139.","journal-title":"Int J Cardiol"},{"key":"964_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1155\/2008\/704045","volume":"2008","author":"M Zhang","year":"2008","unstructured":"Zhang M, Lv XY, Li J, Xu ZG, Chen L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res. 2008;2008:9.","journal-title":"Exp Diabetes Res"},{"issue":"7","key":"964_CR18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1161\/CIRCULATIONAHA.113.008476","volume":"130","author":"D Montaigne","year":"2014","unstructured":"Montaigne D, Marechal X, Coisne A, Debry N, Modine T, Fayad G, et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation. 2014;130(7):554\u201364.","journal-title":"Circulation"},{"issue":"20","key":"964_CR19","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/j.jacc.2009.07.031","volume":"54","author":"EJ Anderson","year":"2009","unstructured":"Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, Neufer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol. 2009;54(20):1891\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"964_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"31","author":"N Hammoudi","year":"2017","unstructured":"Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther. 2017;31(3):233\u201346.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"964_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1253\/circj.CJ-13-1187","volume":"78","author":"Y Teshima","year":"2014","unstructured":"Teshima Y, Takahashi N, Nishio S, Saito S, Kondo H, Fukui A, et al. Production of reactive oxygen species in the diabetic heart. Roles of mitochondria and NADPH oxidase. Circ J. 2014;78(2):300\u20136.","journal-title":"Circ J"},{"issue":"3","key":"964_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1042\/CS20070166","volume":"114","author":"H Bugger","year":"2008","unstructured":"Bugger H, Abel ED. Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin Sci. 2008;114(3):195\u2013210.","journal-title":"Clin Sci"},{"issue":"5","key":"964_CR23","doi-asserted-by":"publisher","first-page":"e005945","DOI":"10.1161\/JAHA.117.005945","volume":"6","author":"X Zhang","year":"2017","unstructured":"Zhang X, Zhang Z, Zhao Y, Jiang N, Qiu J, Yang Y, et al. Alogliptin, a dipeptidyl peptidase-4 inhibitor, alleviates atrial remodeling and improves mitochondrial function and biogenesis in diabetic rabbits. J Am Heart Assoc. 2017;6(5):e005945.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"964_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jtcvs.2004.03.058","volume":"129","author":"N Ad","year":"2005","unstructured":"Ad N, Schneider A, Khaliulin I, Borman JB, Schwalb H. Impaired mitochondrial response to simulated ischemic injury as a predictor of the development of atrial fibrillation after cardiac surgery: in vitro study in human myocardium. J Thorac Cardiovasc Surg. 2005;129(1):41\u20135.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"964_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-319-55330-6_15","volume":"982","author":"N Torrealba","year":"2017","unstructured":"Torrealba N, Aranguiz P, Alonso C, Rothermel BA, Lavandero S. Mitochondria in structural and functional cardiac remodeling. Adv Exp Med Biol. 2017;982:277\u2013306.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"964_CR26","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1006\/jmcc.2001.1378","volume":"33","author":"EJ Lesnefsky","year":"2001","unstructured":"Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. J Mol Cell Cardiol. 2001;33(6):1065\u201389.","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"964_CR27","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1253\/circj.CJ-10-1089","volume":"75","author":"S Kurokawa","year":"2011","unstructured":"Kurokawa S, Niwano S, Niwano H, Ishikawa S, Kishihara J, Aoyama Y, et al. Progression of ventricular remodeling and arrhythmia in the primary hyperoxidative state of glutathione-depleted rats. Circ J. 2011;75(6):1386\u201393.","journal-title":"Circ J"},{"issue":"1","key":"964_CR28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","volume":"17","author":"A Durak","year":"2018","unstructured":"Durak A, Olgar Y, Degirmenci S, Akkus E, Tuncay E, Turan B. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. Cardiovasc Diabetol. 2018;17(1):144.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"964_CR29","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/art.39182","volume":"67","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhao X, Lotz M, Terkeltaub R, Liu-Bryan R. Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor gamma coactivator 1alpha. Arthritis Rheumatol. 2015;67(8):2141\u201353.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"964_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00395-013-0329-1","volume":"108","author":"W Yan","year":"2013","unstructured":"Yan W, Zhang H, Liu P, Wang H, Liu J, Gao C, et al. Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1alpha signaling contributing to increased vulnerability in diabetic heart. Basic Res Cardiol. 2013;108(3):329.","journal-title":"Basic Res Cardiol"},{"issue":"6","key":"964_CR31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","volume":"32","author":"Y Ye","year":"2018","unstructured":"Ye Y, Jia X, Bajaj M, Birnbaum Y. Dapagliflozin attenuates Na(+)\/H(+) exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther. 2018;32(6):553\u20138.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1S","key":"964_CR32","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.amjcard.2017.05.014","volume":"120","author":"M Lehrke","year":"2017","unstructured":"Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Cardiol. 2017;120(1S):S37\u201347.","journal-title":"Am J Cardiol"},{"issue":"2","key":"964_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.tcm.2016.07.008","volume":"27","author":"D Pham","year":"2017","unstructured":"Pham D, Albuquerque Rocha N, McGuire DK, Neeland IJ. Impact of empagliflozin in patients with diabetes and heart failure. Trends Cardiovasc Med. 2017;27(2):144\u201351.","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"964_CR34","doi-asserted-by":"publisher","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","volume":"304","author":"V Vallon","year":"2013","unstructured":"Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, et al. Knockout of Na\u2013glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013;304(2):F156\u201367.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"964_CR35","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.metabol.2009.10.025","volume":"59","author":"D von Lewinski","year":"2010","unstructured":"von Lewinski D, Rainer PP, Gasser R, Huber MS, Khafaga M, Wilhelm B, et al. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism. 2010;59(7):1020\u20138.","journal-title":"Metabolism"},{"issue":"8","key":"964_CR36","doi-asserted-by":"publisher","first-page":"C1174","DOI":"10.1152\/ajpcell.00450.2011","volume":"302","author":"I Sabolic","year":"2012","unstructured":"Sabolic I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, et al. Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol. 2012;302(8):C1174\u201388.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"17","key":"964_CR37","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"Y Lytvyn","year":"2017","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643\u201358.","journal-title":"Circulation"},{"issue":"11","key":"964_CR38","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.amjcard.2016.08.061","volume":"118","author":"H Tang","year":"2016","unstructured":"Tang H, Fang Z, Wang T, Cui W, Zhai S, Song Y. Meta-analysis of effects of sodium\u2013glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am J Cardiol. 2016;118(11):1774\u201380.","journal-title":"Am J Cardiol"},{"issue":"4","key":"964_CR39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"964_CR40","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/jdi.13009","volume":"10","author":"Y Kimura","year":"2019","unstructured":"Kimura Y, Kuno A, Tanno M, Sato T, Ohno K, Shibata S, et al. Canagliflozin, an SGLT2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats. J Diabetes Invest. 2019;10(4):933\u201346.","journal-title":"J Diabetes Invest"},{"issue":"3","key":"964_CR41","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1124\/jpet.118.253666","volume":"368","author":"H Oshima","year":"2019","unstructured":"Oshima H, Miki T, Kuno A, Mizuno M, Sato T, Tanno M, et al. Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and anti-oxidants in diabetic rats. J Pharmacol Exp Ther. 2019;368(3):524\u201334.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"964_CR42","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/1074248418763808","volume":"23","author":"F Younis","year":"2018","unstructured":"Younis F, Leor J, Abassi Z, Landa N, Rath L, Hollander K, et al. Beneficial effect of the SGLT2 inhibitor empagliflozin on glucose homeostasis and cardiovascular parameters in the cohen rosenthal diabetic hypertensive (CRDH) rat. J Cardiovasc Pharmacol Ther. 2018;23(4):358\u201371.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"964_CR43","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/1440-1681.13053","volume":"46","author":"S Takakura","year":"2019","unstructured":"Takakura S, Takasu T. First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats. Clin Exp Pharmacol Physiol. 2019;46(3):266\u201373.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"6","key":"964_CR44","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1139\/cjpp-2018-0466","volume":"97","author":"Y Olgar","year":"2019","unstructured":"Olgar Y, Turan B. A sodium\u2013glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn(2+)-transporters in cardiomyocytes from insulin-resistant metabolic syndrome rats through inhibition of oxidative stress. Can J Physiol Pharmacol. 2019;97(6):528\u201335.","journal-title":"Can J Physiol Pharmacol"},{"issue":"12","key":"964_CR45","doi-asserted-by":"publisher","first-page":"e13741","DOI":"10.14814\/phy2.13741","volume":"6","author":"M Mizuno","year":"2018","unstructured":"Mizuno M, Kuno A, Yano T, Miki T, Oshima H, Sato T, et al. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. Physiol Rep. 2018;6(12):e13741.","journal-title":"Physiol Rep."},{"key":"964_CR46","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.biopha.2018.10.095","volume":"109","author":"CC Yang","year":"2019","unstructured":"Yang CC, Chen YT, Wallace CG, Chen KH, Cheng BC, Sung PH, et al. Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat. Biomed Pharmacother. 2019;109:658\u201370.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"964_CR47","doi-asserted-by":"publisher","first-page":"E57","DOI":"10.3390\/brainsci9030057","volume":"9","author":"MR Hayden","year":"2019","unstructured":"Hayden MR, Grant DG, Aroor AR, DeMarco VG. Empagliflozin ameliorates type 2 diabetes-induced ultrastructural remodeling of the neurovascular unit and neuroglia in the female db\/db mouse. Brain Sci. 2019;9(3):E57.","journal-title":"Brain Sci"},{"key":"964_CR48","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","volume":"9","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Kuschma MC, Hollmann MW. Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol. 2018;9:1575.","journal-title":"Front Physiol"},{"issue":"1","key":"964_CR49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12933-018-0745-5","volume":"17","author":"S Lahnwong","year":"2018","unstructured":"Lahnwong S, Chattipakorn SC, Chattipakorn N. Potential mechanisms responsible for cardioprotective effects of sodium\u2013glucose co-transporter 2 inhibitors. Cardiovasc Diabetol. 2018;17(1):101.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"964_CR50","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/ijms20071680","volume":"20","author":"TI Lee","year":"2019","unstructured":"Lee TI, Chen YC, Lin YK, Chung CC, Lu YY, Kao YH, et al. Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in streptozotocin-induced diabetic rats. Int J Mol Sci. 2019;20(7):1680.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"964_CR51","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.jacc.2016.08.048","volume":"68","author":"D Kotecha","year":"2016","unstructured":"Kotecha D, Lam CS, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol. 2016;68(20):2217\u201328.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"964_CR52","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits. Diabetologia. 2017;60(3):568\u201373.","journal-title":"Diabetologia"},{"key":"964_CR53","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2018;15:335\u201346.","journal-title":"Redox Biol"},{"issue":"11","key":"964_CR54","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1529\/biophysj.107.128587","volume":"94","author":"AR Mehta","year":"2008","unstructured":"Mehta AR, Huang CL, Skepper JN, Fraser JA. Extracellular charge adsorption influences intracellular electrochemical homeostasis in amphibian skeletal muscle. Biophys J. 2008;94(11):4549\u201360.","journal-title":"Biophys J"},{"issue":"1","key":"964_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","volume":"15","author":"H Kusaka","year":"2016","unstructured":"Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):157.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"964_CR56","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1111\/dom.12962","volume":"19","author":"R Chilton","year":"2017","unstructured":"Chilton R, Tikkanen I, Hehnke U, Woerle HJ, Johansen OE. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab. 2017;19(11):1620\u20134.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"964_CR57","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ejhf.1473","volume":"21","author":"SR Yurista","year":"2019","unstructured":"Yurista SR, Sillj\u00e9 HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, et al. Sodium\u2013glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21(7):862\u201373.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"964_CR58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/2047487318755531","volume":"25","author":"MS Usman","year":"2018","unstructured":"Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, et al. Sodium\u2013glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(5):495\u2013502.","journal-title":"Eur J Prev Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0964-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-019-0964-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0964-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T19:14:54Z","timestamp":1606418094000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0964-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0964-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"12 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Experimental Animal Administration Committee of Tianjin Medical University and Tianjin Municipal Commission for Experimental Animal Control.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}